Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Payables (2016 - 2025)

Historic Payables for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $3.7 million.

  • China Pharma Holdings' Payables rose 8637.17% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 8637.17%. This contributed to the annual value of $3.3 million for FY2024, which is 259.14% down from last year.
  • Latest data reveals that China Pharma Holdings reported Payables of $3.7 million as of Q3 2025, which was up 8637.17% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Payables ranged from a high of $6.4 million in Q3 2022 and a low of $1.7 million during Q3 2021
  • In the last 5 years, China Pharma Holdings' Payables had a median value of $3.3 million in 2025 and averaged $3.4 million.
  • As far as peak fluctuations go, China Pharma Holdings' Payables soared by 66818.75% in 2021, and later plummeted by 5603.15% in 2024.
  • Quarter analysis of 5 years shows China Pharma Holdings' Payables stood at $3.1 million in 2021, then skyrocketed by 102.07% to $6.2 million in 2022, then crashed by 44.81% to $3.4 million in 2023, then decreased by 2.59% to $3.3 million in 2024, then grew by 11.68% to $3.7 million in 2025.
  • Its Payables was $3.7 million in Q3 2025, compared to $3.8 million in Q2 2025 and $3.3 million in Q1 2025.